An Eli Lilly & Co. Zepbound injection pen.
Bloomberg / Bloomberg via Getty Images / Bloomberg
hide
tilting legend
Bloomberg / Bloomberg via Getty Images / Bloomberg
Eli Lilly, the manufacturer of drugs behind the successful successful weight loss medication Zepbound, continues four TV companies for having pretended to sold illegal copies of the drug manufactured by aggravating pharmacies.
Compound drugs are not generics. They are rather copies essentially authorized to be manufactured by special pharmacies called composition pharmacies during drug shortages. The shooting, the active ingredient of the Zepbound and the Mounjaro de Lilly for type 2 diabetes, is in shortage for two years until December 19, 2024. The Food and Drug Administration of the United States required an end to make copies in mid-March, but pharmacies could sell actions already produced until it extends or expires. And compounds can usually make personalized drugs for patients with a doctor’s prescription as well as for patients allergic to certain preservatives in drugs, for example.
During the shortage of Zepbound, composition pharmacies filled the gap for patients who were unable to find the brand medication in their pharmacies and patients who did not have a drug insurance cover and could not afford the price of Zepbound for more than $ 1,086.37 per month. For comparison, the compound shooting is sold as little as $ 99 per month.
Now, the shortage of shooting is over and the deadlines for producing new copies of shooting has passed, Eli Lilly represses himself.
“Anyone continued to sell firing composed of mass breaking the law and deceives patients,” Lilly said in a statement from the company sent to NPR. “We will continue to take action to stop those who threaten patient safety and urgently call on regulators and police to do the same.”
Eli Lilly brought prosecution against composition pharmacies earlier this month. Now he has turned his attention to the tele -destile companies selling composed shooting. Wednesday, Lilly filed complaints against Mochi Health, Willow Health, Fella Health and Delilah and Henry Medds.
According to a complaint, Mochi changed his patients to shooting composed with different additives, such as niacinamide. The complaint also alleges having changed patients in different doses of those offered by Eli Lilly. These modifications have been made “at least five times in just eight months”, alleys the complaint, to allow Mochi to continue selling composed shooting.
The existing law prohibits composers from making “essentially” a copy of a drug accessible to existing trade.
Mochi representatives did not respond to requests for comments.
Lilly’s complaint against Henry Meds alleys that the Télésanté company has poorly referenced the drugs and clinical trials approved by Lilly on his website in order to sell more composed versions. Henry Meds and Fella Health are also accused of selling shot in the form of a pill, which has never been approved by the FDA. “Fella even tells patients that her oral drug not tested is better than approved drugs from Lilly,” said Lilly’s complaint against Fella.
And the complaint against Willow Health says that Willow wrongly claimed to have developed the first “Cosmetics” GLP-1. “The FDA has never approved any form of shooting for aesthetic weight loss,” said Lilly’s complaint, adding that Lilly manufactures the only firzepatid approved by the FDA.
Henry Medds, Fella Health and Willow Health did not respond to requests for NPR comments.
On April 1, Eli Lilly continued two composition pharmacies: Strive AT Embower. Strive says to NPR that she will retaliate, and Empower said in a press release published on her website: “We hold next to our mission and the patients and providers who depend on it.”
Scott Brunner, CEO of the Alliance for Pharmacy Compounding, a advocacy group for composition pharmacies, refused to comment on specific proceedings or companies. However, in an NPR email, he explained that compounds only produce drugs when a prescriber sends a prescription.
“I fear that there is no light line on this question of the practice of the business of medicine in relation to the legitimate personalization of a drug based on the judgment of a prescriber who really interacted with a patient,” he wrote. “The FDA advice clearly authorizes the second, but the first is to some extent in the spectator’s eye. In these new prosecution Lilly, (this) seems that the spectator will be a federal judge.”
